[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].

We, in the Department of Obstetrics and Gynecology, Kansai Medical College, conducted an evaluation of the usefulness and safety of granisetron hydrochloride used for nausea and vomiting due to chemotherapy in patients with gynecological malignant tumors, with an additional study of the efficacy of different regimens. The subjects were 9 patients in whom 16 courses of CAP therapy were given (group A) and 13 patients in whom 24 courses of CAP therapy were given (group B). Granisetron hydrochloride 3 mg/body was administered by intravenous drip in the two groups before chemotherapy. Clinical symptoms of nausea, vomiting, and anorexia were observed for 2 days after anticancer drugs were administered in order to evaluate its efficacy. The percentage of patients who responded as "effective" or better was 90.0%. In different regimens, the efficacy was 93.8% in group A and 87.5% in group B. These results indicated clinically high usefulness in both groups. No side effects related to granisetron hydrochloride were found in this study.